Latest Blockchain news from around the world

What to anticipate when Altria (MO) reviews Q2 2023 earnings outcomes


Shares of Altria Group, Inc. (NYSE: MO) stayed inexperienced on Friday. The inventory has dropped over 3% previously three months. The tobacco large is scheduled to report its second-quarter 2023 earnings outcomes on Tuesday, August 1, earlier than market open. Right here’s a take a look at what to anticipate from the earnings report:


Analysts are projecting revenues of $5 billion for Q2 2023 which compares to $5.37 billion within the prior-year quarter. Within the first quarter of 2023, revenues declined 2.9% year-over-year to $5.7 billion.


The consensus estimate for Q2 2023 EPS is $1.17, which compares to $1.26 within the year-ago interval. In Q1 2023, adjusted EPS rose 5.4% YoY to $1.18.

Factors to notice

In Q1, Altria noticed revenues within the Smokeable Merchandise section lower 3% resulting from decrease cargo volumes. Home cigarette cargo quantity dropped 11.4% in Q1. Cigarette volumes have been pressured throughout the trade resulting from excessive inflation and its impacts on client discretionary revenue, which have led to shifts in buying behaviors of people who smoke. For Altria, these pressures had been offset to an extent by greater pricing. This development might have continued in Q2.

The corporate is prone to profit from progress in oral nicotine pouch merchandise, which have continued to develop their share of the whole oral tobacco class. In Q1, retail share for on! nicotine pouches grew to six.5%. Oral tobacco merchandise grew income by 2.4% in Q1, helped by greater pricing which offset quantity declines.

Altria has accomplished the acquisition of NJOY Holdings, which now provides it entry to the latter’s portfolio of e-vapor merchandise. E-vapor has been a very fashionable selection for transferring people who smoke to different merchandise. Altria is targeted on rising the adoption of NJOY ACE, which is, as of now, the one pod-based e-vapor product to obtain advertising and marketing authorization from the FDA. Additional particulars on this transaction and future plans for e-vapor choices are value watching.

Leave A Reply

Your email address will not be published.